CAJ | 학술논문

目的：探讨利妥昔单抗联合 CHOP 方案治疗弥漫大 B 细胞淋巴瘤(DLBCL)对患者远期生存率的影响。方法将84例初治 DLBCL 患者随机分为对照组和观察组，各42例。对照组患者采用传统 CHOP 方案化疗，观察组患者采用利妥昔单抗联合 CHOP(R － CHOP)方案化疗，观察疗效指标，比较两组患者不良反应发生率间差异。结果观察组患者完全缓解（CR）率较对照组显著提高（ P <0.05），两组患者部分缓解（PR）率未见明显差异（ P >0.05）。观察组患者总有效率较对照组显著提高（ P <0.05）。两组患者1年无进展生存（PFS）率、总体生存（OS）率等间均无明显差异（ P >0.05），而观察组患者3年 PFS 率及 OS 率均较对照组明显增高（ P <0.05）。治疗过程中两组患者不良事件发生率未见明显差异（ P >0.05）。结论 R － CHOP 方案治疗 DLBCL 过程安全、有效，较传统方案联合方案能显著改善患者长期生存率。
목적：탐토리타석단항연합 CHOP 방안치료미만대 B 세포림파류(DLBCL)대환자원기생존솔적영향。방법장84례초치 DLBCL 환자수궤분위대조조화관찰조，각42례。대조조환자채용전통 CHOP 방안화료，관찰조환자채용리타석단항연합 CHOP(R － CHOP)방안화료，관찰료효지표，비교량조환자불량반응발생솔간차이。결과관찰조환자완전완해（CR）솔교대조조현저제고（ P <0.05），량조환자부분완해（PR）솔미견명현차이（ P >0.05）。관찰조환자총유효솔교대조조현저제고（ P <0.05）。량조환자1년무진전생존（PFS）솔、총체생존（OS）솔등간균무명현차이（ P >0.05），이관찰조환자3년 PFS 솔급 OS 솔균교대조조명현증고（ P <0.05）。치료과정중량조환자불량사건발생솔미견명현차이（ P >0.05）。결론 R － CHOP 방안치료 DLBCL 과정안전、유효，교전통방안연합방안능현저개선환자장기생존솔。
Objective To investigate the therapeutic effect of diffuse large B cell lymphoma(DLBCL) in patients with long - term sur-vival rate of rituximab combined with COPD scheme. Methods 84 cases of untreated diffuse large B cell lymphoma patients were ran-domly divided into control group and observation group, 42 cases in each group. The control group was treated by traditional CHOP chemotherapy, the observation group were treated by chemotherapy of R - CHOP regimen. Results Patients in the observation group the rate of CR was significantly higher than the control group ( P < 0. 05), the rate of PR between two groups had no significant differ-ences ( P > 0. 05) . Comparing the total effective rate, patients in the observation group was significantly higher than the control group ( P < 0. 05). There were no significant difference between the 1 year PFS rate and OS rate between two groups ( P > 0. 05), while the patients in the observation group 3 year PFS rate and OS rate were increased significantly compared with control group( P < 0. 05) . Two groups of patients with adverse events during the treatment there was no significant difference between the incidence ( P > 0. 05). Conclusion Rituximab combined with CHOP regimen in the treatment of diffuse large B cell lymphoma, effective process safety. Compared with the traditional scheme, the combination scheme can significantly improve the long - term survival of patients.